The Impact Initiatives and Research Coordination (IRC) unit is responsible for the priority setting and coordination of research and development across the One Health spectrum. It develops and supports global initiatives, innovative partnerships and targeted instruments to enhance the global AMR response, in close collaboration with bilateral and multilateral financing institutions and other stakeholders. This includes:

• Identifies priority research agenda and priority pathogens lists for bacterial and fungal infections in the context of drug resistance;
• Sets the priority research agenda and priority pathogens lists for bacterial and fungal infections;
• Analyses the clinical and preclinical antibacterial pipeline on an annual basis;
• Supports the Global Antibiotic Research & Development Partnership (GARDP), a not-for-profit drug developer aiming to develop five new treatments by 2025 to fight drug-resistant infections;
• Advocates for increased investment and coordination for research and development (including implementation research) on AMR;
• Developing global norms and standards, including revisions to the WHO List of Critically Important Antimicrobials.